SCHEMBL6319355

SCHEMBL6319355

O=C1Cc2c(cccc2-c2ccc(F)cc2)N1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 7/20 0.49
CDK5 Q00535 7/20 0.49
CDK5R1 Q15078 7/20 0.49
CCNB2 O95067 6/20 0.49
CDK1 P06493 6/20 0.49
CCNB1 P14635 6/20 0.49
CCNB3 Q8WWL7 6/20 0.49
PIP4K2A P48426 1/20 0.48
PIP4K2B P78356 1/20 0.48
ABL1 P00519 1/20 0.45
CCNT1 O60563 1/20 0.43
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
CDK9 P50750 1/20 0.43
CCNA1 P78396 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
JAK2 O60674 1/20 0.42
AHR P35869 1/20 0.41
PDK2 Q15119 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321586 0.86 GSK3B (0.48) GSK3BCDK5CDK5R1CCNB2CDK1
SCHEMBL16090379 0.85 BRD4 (0.52) GSK3BCDK5CDK5R1CCNB2CDK1
SCHEMBL5843496 0.85 JAK2 (0.51) GSK3BCDK5CDK5R1CCNB2CDK1
SCHEMBL155873 0.84 GSK3B (0.50) GSK3BCDK5CDK5R1CCNB2CDK1
SCHEMBL6324288 0.84 CCNB2 (0.49) GSK3BCDK5CDK5R1CCNB2CDK1
SCHEMBL6321102 0.84 CCNB2 (0.52) GSK3BCDK5CDK5R1CCNB2CDK1
SCHEMBL152990 0.81 PIP4K2A (0.51) GSK3BCDK5CDK5R1CCNB2CDK1
SCHEMBL29899546 0.81 PIP4K2A (0.51) GSK3BCDK5CDK5R1CCNB2CDK1
SCHEMBL6321256 0.80 GSK3B (0.52) GSK3BCDK5CDK5R1CCNB2CDK1
SCHEMBL6320304 0.80 GSK3B (0.52) GSK3BCDK5CDK5R1CCNB2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 GSK3B 81/4885CDK5 1/4885CDK5R1 19/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 GSK3B 81/4885CDK5 1/4885CDK5R1 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.